Autologous versus donor cells: the difference in Korean clinic treatment

Autologous means cells taken from the guest's own body — adipose tissue or bone marrow, for example. The advantage is no immune rejection issue of the kind seen with another person's tissue.

The limitation is that quality and quantity follow bodily condition: older guests, or those with chronic disease, smoking history or high inflammation, may yield lower-potential cells — hence the emphasis on preparing the body before harvest.

Donor cells, such as those from umbilical tissue, are described as more consistent because they are screened and quality-controlled in batches, but require rigorous infectious disease testing and documentation.

In Korea, cell products fall under public health regulation, and Cellora's March 2025 designation as an advanced regenerative medicine institution places it within that framework.

For Thai guests, the crucial issue is continuity at home: what is legal in Korea may not be continuable in Thailand, so plan follow-up in line with Thai law.

Always ask: what is the cell source, what testing was done, is documentation provided, and if an adverse event occurs, whom do you contact and how is it reported.